Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | PET/CT imaging study of the amyloid-reactive peptide 124I-AT-01 to detect systemic amyloidosis

Jonathan Wall, PhD, University of Tennessee Graduate School of Medicine, Knoxville, TN, comments on the results of a first-in-human PET/CT imaging study (NCT03678259) of the amyloid-reactive peptide 124I-AT-01 for the detection of systemic amyloidosis. Overall, the study showed a high percentage of patient-based sensitivity as well as a high rate of positive 124I-AT-01 uptake in the heart in patients with both AL and ATTR amyloidosis.

This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Co-founder and shareholder in Attralus Inc. Inventor and patent holder related to amyloid-binding peptide technologies and amyloid-reactive antibody. Receives research funding from Attralus Inc.